✦ LIBER ✦

In vivo recovery and early half-life of infused factor VIII in haemophilia A

✍ Scribed by Carol K. Kasper

Book ID: 108769232
Publisher: John Wiley and Sons
Year: 1995
Tongue: English
Weight: 238 KB
Volume: 1
Category: Article
ISSN: 1351-8216
DOI: 10.1111/j.1365-2516.1995.tb00034.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Factor VIII recovery after a single infu

Factor VIII recovery after a single infusion of recalibrated ReFacto® in 14 severe haemophilia A patients

✍ T. LAMBERT; C. GUÉROIS; V. GAY; N. STIELTJES; M.-A. BERTRAND; A. DERLON; M. SIGA 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 486 KB

In vitro and in vivo stability of dilute

In vitro and in vivo stability of diluted recombinant factor VIII for continuous infusion use in haemophilia A

✍ S. REVEL-VILK; V. S. BLANCHETTE; M. SCHMUGGE; D. S. CLARK; D. LILLICRAP; M. L. R 📂 Article 📅 2010 🏛 John Wiley and Sons 🌐 English ⚖ 209 KB

Discrepant in vivo recovery of factor VI

Discrepant in vivo recovery of factor VIII:C following infusion of two different monoclonal factor VIII preparations

✍ Muhammad Shurafa 📂 Article 📅 1994 🏛 Springer US 🌐 English ⚖ 223 KB

Measurement of global haemostasis in sev

Measurement of global haemostasis in severe haemophilia A following factor VIII infusion

✍ S. J. Lewis; E. Stephens; G. Florou; N. J. Macartney; L. S. Hathaway; J. Knippin 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 703 KB

Effectiveness of factor VIII infusions i

Effectiveness of factor VIII infusions in haemophilia A patients with high responding inhibitors

✍ S. Kasuda; I. Tanaka; M. Shima; T. Matsumoto; Y. Sakurai; K. Nishiya; A. R. Gile 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 112 KB

In vivo recovery and half-life time of a

In vivo recovery and half-life time of a steam-treated factor IX concentrate in hemophilia B patients

✍ K�hler, M. ;Seifried, E. ;Hellstern, P. ;Pindur, G. ;Miyashita, C. ;M�rsdorf, S. 📂 Article 📅 1988 🏛 Springer-Verlag ⚖ 520 KB

Factor IX (FIX) recovery and half-life was measured in ten hemophilia B patients under standardized conditions. Each patient received a steam-treated high-purity factor IX concentrate at a dose of 19-39 U/kg body weight. FIX activity was determined using a one-stage assay, which was calibrated again